KRAS and pancreatic ductal adenocarcinoma: In line with the Hsp90 connection to K-Ras, a synergistic activity of Hsp90 inhibitors with MAPK-pathway inhibitors in KRAS mutant pancreatic ductal adenocarcinoma was reported [54].